E2 ModerateModerate confidencePEM ?Cross-SectionalPeer-reviewedMachine draft
Impact of COVID-19 on myalgic encephalomyelitis/chronic fatigue syndrome-like illness prevalence: A cross-sectional survey.
Wood, Mariah S, Halmer, Nicole, Bertolli, Jeanne et al. · PloS one · 2024 · DOI
Quick Summary
This study found that about 1.67% of adults in a large California health system have ME/CFS-like illness. While COVID-19 can trigger ME/CFS in some people, only about 14% of those with ME/CFS-like illness developed it after having COVID-19. People with ME/CFS-like illness reported significant difficulties with physical activities, work, relationships, and mental health compared to those without the condition.
Why It Matters
This study provides important population-level estimates of ME/CFS prevalence in a large, diverse healthcare system and clarifies that while COVID-19 can trigger ME/CFS in some individuals, it was not responsible for a substantial increase in ME/CFS cases during the study period. The finding that ME/CFS affects nearly 1.7% of adults underscores the significant public health burden and urgent need for improved diagnosis and treatment options.
Observed Findings
- Approximately 1.67% of adults in the KPNC population had ME/CFS-like illness based on self-reported symptoms.
- Of all persons with ME/CFS-like illness, 14.12% developed the condition after COVID-19.
- Among those with post-COVID ME/CFS-like illness, cases were more likely to be unvaccinated and to have had COVID-19 before June 1, 2021.
- All persons with ME/CFS-like illness reported significant impairment in physical, mental, emotional, social, and occupational functioning.
- COVID-19 did not substantially increase overall ME/CFS-like illness prevalence in the population during the study period.
Inferred Conclusions
- ME/CFS-like illness represents a notable public health burden affecting approximately 1.67% of the adult population in this large integrated health system.
- While COVID-19 can trigger ME/CFS in a subset of individuals, it did not cause a substantial increase in overall ME/CFS prevalence in this population.
- Increased clinical awareness, diagnostic capacity, and targeted treatments for ME/CFS are needed to address the significant functional impairment associated with this condition.
- Vaccination status and timing of COVID-19 infection may be relevant factors in post-COVID ME/CFS development.
Remaining Questions
What This Study Does Not Prove
This study does not establish a causal link between COVID-19 and ME/CFS development—it only shows that 14% of ME/CFS cases reported onset after COVID-19. The cross-sectional design cannot determine temporal relationships or rule out recall bias. The findings also cannot be generalized beyond integrated health systems or to populations with different vaccination and infection patterns.
Tags
Symptom:Post-Exertional MalaiseCognitive DysfunctionFatigue
Phenotype:Infection-TriggeredLong COVID Overlap
Method Flag:PEM Not DefinedMixed Cohort